# Kytopen

> Kytopen is a Cambridge, Massachusetts biotech and MIT spinout building Flowfect, a non-viral, continuous-flow platform that uses fluid flow plus electric fields to deliver mRNA, DNA and CRISPR payloads into cells. The technology aims to engineer hundreds of billions of cells in minutes, removing a major bottleneck in discovering, developing and manufacturing advanced cell therapies like CAR-T and NK-cell treatments.

- **Founded:** 2017
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Cullen Buie (Co-founder; MIT Associate Professor of Mechanical Engineering), Paulo Garcia (Co-founder; former MIT postdoc / research scientist)
- **Team size:** ~26 employees
- **Products:** Flowfect (platform), Flowfect Discover, Flowfect Tx
- **Notable:** MIT spinout commercializing Flowfect non-viral, continuous-flow cell engineering technology, Raised a $30M Series A and a Series B led by Telegraph Hill Partners (April 2026), Independent Charles River study showed Flowfect Tx outperformed conventional electroporation on viability and editing efficiency

## Products & services

- **Flowfect (platform)** — Non-viral, continuous-flow transfection technology that combines fluid flow with electric fields to deliver mRNA, DNA, RNP and CRISPR payloads into mammalian cells while preserving cell health and yield.
- **Flowfect Discover** — A 96-well discovery and optimization system for rapidly screening transfection conditions across many cell types and payloads.
- **Flowfect Tx** — A GMP-ready, clinical- and manufacturing-scale platform that processes billions of cells in minutes in a closed, automated continuous-flow system, designed to bridge discovery to manufacturing.

## Achievements

- MIT spinout commercializing Flowfect non-viral, continuous-flow cell engineering technology
- Raised a $30M Series A and a Series B led by Telegraph Hill Partners (April 2026)
- Independent Charles River study showed Flowfect Tx outperformed conventional electroporation on viability and editing efficiency
- Awarded a Phase II NIH/NIAID SBIR Fast-Track grant of $1.6M for engineered NK-cell work
- Flowfect platform selected for GMP manufacture of an engineered cell therapy heading toward IND/clinical studies
- Demonstrated non-viral engineering of hard-to-transfect monocyte-derived macrophages

## Latest updates

- **2026-04** — Closed Series B financing led by Telegraph Hill Partners; added Matthew Mackowski to the board to fuel global commercial expansion.
- **2025-05** — Announced collaboration with Bio-Techne integrating the TcBuster system with Flowfect; data presented at ISCT in New Orleans.
- **2024-10** — Published advances using Flowfect for non-viral engineering of monocyte-derived macrophages.
- **2024-09** — Charles River comparative study showed Flowfect Tx outperformed two conventional electroporation platforms.
- **2024-08** — Received a Phase II NIH/NIAID SBIR Fast-Track grant of $1.6M for engineered NK-cell studies.

## Links

- Website: https://kytopen.com
- LinkedIn: https://www.linkedin.com/company/kytopen
- Twitter/X: https://twitter.com/kytopen
- YouTube: https://www.youtube.com/watch?v=NNbjvU8yhd8

---

Profile page: https://yespress.io/kytopen
Published by YesPress — https://yespress.io
Last updated: 2026-06-08